Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Supernus Announces Year-End and Fourth Quarter 2012 Earnings Conference Call and Webcast



Supernus Announces Year-End and Fourth Quarter 2012 Earnings Conference Call
and Webcast

ROCKVILLE, Md., March 7, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), today announced that the Company expects to report the
quarter and year ending December 31, 2012 financial results after the market
closes on Thursday, March 14, 2013. Supernus will host a conference call at
5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to review the financial
results, as well as provide an update on other business matters of the
Company.

A live webcast will be available at www.supernus.com. The webcast will be
archived on the Company's website for 30 business days following the live
call.

Callers should dial in approximately 10 minutes prior to the start of the
call. The phone number to join the conference call is +1 (877) 288-1043 (U.S.
and Canada) or +1 (970) 315-0267 (international and local). The access code
for the live call is 99051365.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has one marketed product for
epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one tentatively
approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The
Company is also developing several product candidates in psychiatry to address
large market opportunities in ADHD, including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive aggression
in ADHD and SPN-812 for ADHD.

CONTACT: Jack Khattar, President & CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement